Tessellate BIO

Recent Finacing

Seed

Recent Raise

$8.4M

Tessellate BIO is a preclinical stage biotechnology company that develops precision oncology medicines targeting the DNA damage response and cancers relying on Alternative Lengthening of Telomeres (ALT).

Total Funding

$8.4M

Headquarters

Nardeen, Netherlands

Founded

N/A

Website

tessellatebio.com

Focus Areas

precision oncology medicines

DNA damage response

Alternative Lengthening of Telomeres (ALT)

Investors